Publisher
Springer Science and Business Media LLC
Subject
Energy Engineering and Power Technology,Fuel Technology
Reference8 articles.
1. Hunig, T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nature Rev. Immunol. 12, 317–318 (2012).
2. Horvath, C. et al. Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nature Rev. Immunol. 31 Aug 2012 (doi:10.1038/nri3192-c1).
3. Gogishvili, T. et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 4, e4643 (2009).
4. Eastwood, D. et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161, 512–526 (2010).
5. Romer, P. S. et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118, 6772–6782 (2011).
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献